E. coli-derived rhBMP-2 offers similar fusion success to AIBG in posterolateral lumbar fusion
Efficacy of Escherichia coli-derived recombinant human bone morphogenetic protein-2 in posterolateral lumbar fusion: an open, active-controlled, randomized, multicenter trialSpine J. 2017 Dec;17(12):1866-1874
Did you know you're eligible to earn 0.5 CME credits for reading this report? Click Here
100 patients scheduled for posterolateral fusion due to severe spinal stenosis, grade 1 spondylolisthesis, or spondylolysis were randomized to graft material of either Escherichia coli-derived recombinant human bone morphogenetic protein-2 (rhBMP-2) in a hydroxyapatite carrier or an autologous iliac crest bone graft. Patients were assessed primarily for fusion success on CT at 12 and 24 weeks. Sec...
Learn about our AI Driven
High Impact Search Feature
The OE High Impact metric uses AI to determine the impact a study will have by considering the content of the article itself. Built using the latest advances of natural language processing techniques. OE High Impact predicts an article’s future number of citations than impact factor alone.Continue